Finasteride and gynaecomastia are linked through a well-recognised hormonal mechanism: by reducing dihydrotestosterone (DHT), finasteride shifts the androgen-to-oestrogen ratio, which can stimulate breast glandular tissue in some men. Listed as an uncommon adverse effect in the UK Summary of Product Characteristics for both the 1 mg (hair loss) and 5 mg (BPH) formulations, gynaecomastia is a real-world concern acknowledged by the MHRA and EMA. This article explains how finasteride affects hormones, how common breast changes are, what symptoms to look out for, and what to do if you are affected.

How Finasteride Works and Its Effect on Hormones

Finasteride blocks 5-alpha reductase, reducing DHT by 60–90% depending on dose, which modestly raises testosterone and shifts the androgen-to-oestrogen ratio towards greater oestrogenic activity in some men.

Finasteride is a 5-alpha reductase inhibitor — a class of medicine that works by selectively blocking the type II isoenzyme (and, to a lesser extent, type III) of 5-alpha reductase, the enzyme responsible for converting testosterone into dihydrotestosterone (DHT). DHT is a potent androgen that plays a significant role in conditions such as male pattern hair loss (androgenetic alopecia) and benign prostatic hyperplasia (BPH). By reducing DHT levels, finasteride helps slow hair loss and reduce prostate size, depending on the indication.

Not sure if this is normal? Chat with one of our pharmacists →

The degree of DHT suppression varies by dose and tissue. With the 1 mg dose used for hair loss, serum DHT typically falls by approximately 60–70%; with the 5 mg dose used for BPH, intraprostatic and scalp DHT reductions can be higher — up to around 80–90%. Alongside this, serum testosterone levels rise modestly (by approximately 10%) as a compensatory effect.

Because finasteride interferes with androgen metabolism, it inevitably alters the hormonal balance within the body. When DHT levels fall, the ratio of oestrogen to androgens can shift. In some men, small increases in serum oestradiol have been observed, though levels typically remain within the normal range. The net effect is a relative shift in the androgen-to-oestrogen ratio towards greater oestrogenic activity, which can have effects on hormone-sensitive tissues — including breast tissue.

This hormonal shift is the underlying mechanism thought to contribute to certain side effects associated with finasteride, including changes in libido, sexual function, and, in some cases, breast-related changes. Understanding this mechanism helps explain why breast tissue changes are a recognised, if uncommon, consideration when prescribing finasteride.

The Link Between Finasteride and Gynaecomastia

Gynaecomastia is a listed adverse effect in the UK SmPCs for both finasteride 1 mg and 5 mg; it occurs when reduced DHT disrupts the androgen-to-oestrogen ratio, stimulating breast glandular tissue proliferation.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — is listed as a known adverse effect of finasteride in the Summary of Product Characteristics (SmPC) for both its 1 mg formulation (used for hair loss, e.g., Propecia) and its 5 mg formulation (used for BPH, e.g., Proscar), as published on the electronic Medicines Compendium (eMC). The European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have both acknowledged breast-related changes — including gynaecomastia and breast tenderness — in their product information and pharmacovigilance data.

The proposed mechanism relates directly to the hormonal changes described above. When the androgen-to-oestrogen ratio is disrupted, breast glandular tissue — which is sensitive to oestrogen stimulation — may begin to proliferate. This is the same fundamental process that underlies gynaecomastia caused by other medicines and medical conditions.

Gynaecomastia and breast tenderness are classified as uncommon adverse effects in both the 1 mg and 5 mg SmPCs. Post-marketing reports suggest that cases have been reported at both doses; whilst more reports exist in the BPH population (where the 5 mg dose is used), gynaecomastia has also occurred in men taking the 1 mg dose for hair loss. Any apparent difference in reporting rates may reflect differences in the populations treated and duration of use rather than a confirmed dose-response relationship.

Importantly, the SmPCs for both formulations include a specific caution that any breast changes — including lumps, pain, or nipple discharge — should prompt patients to seek prompt medical assessment, due to rare reports of male breast cancer in men taking finasteride. Although a causal link with male breast cancer has not been established, this caution is included in the product information and should be communicated to patients before treatment begins.

In most cases of gynaecomastia, the condition is reversible upon discontinuation of finasteride, particularly when identified early, though resolution is not guaranteed in all individuals.

How Common Is Gynaecomastia as a Side Effect

Gynaecomastia is classified as uncommon, affecting an estimated 1 in 100 to 1 in 1,000 finasteride users, based on clinical trial data in UK SmPCs; post-marketing reports via the Yellow Card scheme confirm real-world cases.

In line with the UK SmPCs for both finasteride 1 mg (Propecia) and finasteride 5 mg (Proscar), gynaecomastia — encompassing breast enlargement and breast tenderness — is classified as an uncommon adverse effect, meaning it is estimated to affect between 1 in 100 and 1 in 1,000 users. Prescribers and patients should be aware that frequency classifications in SmPCs are based on clinical trial data, and that post-marketing surveillance may capture additional cases not reflected in these figures.

Some clinical trial data for the 5 mg formulation have reported breast-related adverse effects in a small percentage of participants; however, these figures vary by study design, population, and duration of follow-up, and should be interpreted in the context of the specific trial rather than as a general population estimate. Where higher figures have been cited in the literature, they typically reflect combined endpoints (breast tenderness plus enlargement) in older men with BPH over extended follow-up periods.

It is important to contextualise these figures. The background rate of gynaecomastia in adult men is not negligible — physiological or idiopathic gynaecomastia affects a significant proportion of men at various life stages, particularly during puberty and older age. This means that not every case of gynaecomastia occurring in a man taking finasteride is necessarily caused by the medication. Other contributing factors — including obesity, alcohol use, other medicines (such as spironolactone, certain antipsychotics, or anabolic steroids), and underlying medical conditions — must also be considered.

Nonetheless, the temporal association between starting finasteride and the onset of breast changes is clinically meaningful and should not be dismissed. Post-marketing reports submitted to the MHRA via the Yellow Card scheme have included cases of gynaecomastia, reinforcing that this is a real-world concern beyond controlled trial settings. Patients and prescribers should be aware of this possibility before and during treatment.

Recognising Symptoms and When to Seek Medical Advice

Key symptoms include breast tenderness, a firm subareolar lump, swelling, or nipple discharge; any new breast lump in a man taking finasteride warrants prompt clinical assessment, with urgent review for red-flag features.

Gynaecomastia associated with finasteride typically presents as:

• Breast tenderness or sensitivity, often one of the earliest signs

• A firm, rubbery lump or disc of tissue beneath the nipple area

• Swelling or enlargement of one or both breasts

• Nipple discharge in rare cases

Symptoms may develop gradually over weeks to months after starting finasteride, though onset can vary. It is important to distinguish gynaecomastia — which involves true glandular tissue — from pseudogynaecomastia, which is fatty tissue accumulation without glandular proliferation and is not related to finasteride use.

Patients should contact their GP promptly if they notice any new breast lump, persistent breast pain, or nipple discharge whilst taking finasteride. Although gynaecomastia is benign, any new breast lump in a male patient warrants clinical assessment to exclude other causes. The SmPC for finasteride specifically notes that breast changes should be assessed promptly due to rare reports of male breast cancer in men taking finasteride.

Certain features should prompt urgent medical review and may warrant a suspected cancer referral under NICE NG12 (Suspected cancer: recognition and referral) criteria. These red-flag features include:

• A hard or irregular breast lump

• Bloody or unilateral nipple discharge

• Nipple inversion or skin tethering

• Palpable axillary lymph nodes

• Unexplained weight loss, fatigue, or skin changes around the nipple

The NHS advises that any unexplained breast lump in a man should be evaluated by a healthcare professional without delay. Patients should not stop finasteride abruptly without first speaking to their prescriber, as this decision should be made in the context of the overall treatment plan and the benefits the medicine is providing.

Managing Gynaecomastia If You Are Taking Finasteride

Management begins with clinical assessment including hormone bloods and medication review; discontinuing finasteride often resolves early gynaecomastia, while persistent cases may require SERMs such as tamoxifen or surgical intervention.

If gynaecomastia is confirmed or suspected in a patient taking finasteride, the first step is a thorough clinical assessment. This typically involves a physical examination — including testicular examination to exclude a testicular tumour as a secondary cause — alongside a review of all current medications and relevant investigations. Blood tests may include liver function tests, thyroid function, and hormone levels (testosterone, sex hormone-binding globulin [SHBG], oestradiol, LH, FSH, and prolactin). Where a testicular or other tumour is suspected, serum hCG and AFP should also be measured, and testicular ultrasound considered. Renal function testing is not routinely indicated unless there is a specific clinical reason.

In many cases, discontinuing finasteride leads to resolution or significant improvement of gynaecomastia, particularly if the condition is identified early. However, if glandular tissue has been present for more than 12 months, fibrosis may have occurred, making spontaneous resolution less likely even after stopping the medicine. This underlines the importance of early reporting and prompt clinical review.

For patients in whom finasteride provides significant clinical benefit — for example, those using it for BPH or experiencing substantial hair loss — the decision to continue or discontinue should be made collaboratively between the patient and their prescriber, weighing the benefits against the impact of the side effect. In some cases, referral to an endocrinologist or a breast surgeon may be appropriate.

Experiencing these side effects? Our pharmacists can help you navigate them →

In persistent or symptomatic cases of gynaecomastia, treatment options include:

• Pharmacological management: Selective oestrogen receptor modulators (SERMs) such as tamoxifen have been used off-label in early or painful gynaecomastia, with some evidence of benefit from limited trial data. This approach is not covered by a specific NICE guideline on gynaecomastia and should be considered under specialist guidance (endocrinology or breast surgery). Pharmacological treatment is generally less effective once fibrosis has established.

• Surgical intervention: Subcutaneous mastectomy may be considered for established, fibrotic gynaecomastia that does not resolve with conservative measures.

Patients should be reassured that gynaecomastia related to finasteride is a recognised and manageable condition, and that support is available through their GP or specialist.

Guidance from the MHRA and Talking to Your GP

The MHRA requires prescribers to counsel patients about gynaecomastia before starting finasteride; patients experiencing breast changes should speak to their GP promptly and report via the Yellow Card scheme.

The MHRA has included gynaecomastia and breast tenderness in the official product information for finasteride-containing medicines available in the UK. Prescribers are expected to counsel patients about this potential side effect before initiating treatment, in line with good prescribing practice and informed consent principles.

In 2024, the MHRA issued a Drug Safety Update on finasteride, introducing a patient alert card for the 1 mg formulation and reinforcing the need for prescribers to counsel patients about the full range of potential adverse effects — including sexual side effects and psychiatric effects such as depression — before starting treatment. Prescribers should ensure patients are aware of this updated safety information.

For the management of lower urinary tract symptoms due to BPH, clinicians should refer to NICE CG97 (Lower urinary tract symptoms in men: management) and NICE CKS: Lower urinary tract symptoms in men, which provide guidance on the use of 5-alpha reductase inhibitors including finasteride and considerations around deprescribing. For androgenetic alopecia, relevant UK primary care guidance includes NICE CKS: Alopecia and guidance from the British Association of Dermatologists. There is no standalone NICE technology appraisal or clinical guideline specific to male pattern hair loss. Shared decision-making — including discussion of the full side-effect profile — is central to prescribing in both indications.

Patients who experience breast changes whilst taking finasteride are encouraged to report these via the Yellow Card scheme (available at yellowcard.mhra.gov.uk), which helps the MHRA monitor the safety of medicines in real-world use.

If you are taking finasteride and have concerns about gynaecomastia or any other side effects, speaking to your GP is the most appropriate first step. Your GP can:

• Assess any breast changes and arrange further investigations if needed

• Review your current medication and consider whether finasteride remains the most suitable option

• Refer you to a specialist (endocrinologist, urologist, or breast surgeon) if clinically indicated

• Support you in reporting the side effect via the Yellow Card scheme

It is important not to stop finasteride without medical advice, particularly if it is being used to manage BPH, as abrupt discontinuation may lead to a return of urinary symptoms. Open communication with your healthcare team ensures that any side effects are managed safely and that your treatment continues to meet your individual needs.

Frequently Asked Questions